Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ KLRG1 Recombinant Rabbit Monoclonal Antibody (8E11)
Rabbit Recombinant Monoclonal Antibody
Supplier: Invitrogen™ MA550022
Description
KLRG1 Recombinant Monoclonal Antibody for Flow, ELISA
KLRG1 (Killer cell lectin-like receptor G1, MAFA, 2F1-Ag) is a homodimeric member of the lectin-like type 2 transmembrane receptor family whose members contain characteristic immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in their cytoplasmic domains. These ITIMs interact with the SH2 domains of protein phosphatases such as SHP-1. KLRG1 is an inhibitory receptor that is expressed on natural killer (NK) cells and certain T cells. NK cells are involved in the lysis of tumor cells and virus-infected cells, and mediate humoral and cell-mediated immune responses.
Specifications
KLRG1 | |
Recombinant Monoclonal | |
1.64 mg/mL | |
PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 | |
Q96E93 | |
Klrg1 | |
A synthesized peptide derived from human KLRG1. | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
ELISA, Flow Cytometry | |
8E11 | |
Unconjugated | |
Klrg1 | |
2F1; 2F1-Ag; CLEC15A; C-type lectin domain family 15 member A; C-type lectin domain family 15, member A; ITIM-containing receptor MAFA-L; killer cell lectin like receptor G1; killer cell lectin-like receptor subfamily G member 1; killer cell lectin-like receptor subfamily G, member 1; Klrg1; Mafa; MAFA-2F1; MAFAL; MAFA-L; MAFA-LIKE; MAFA-like receptor; Mast cell function-associated antigen; mast cell function-associated antigen (ITIM-containing); mast cell function-associated antigen 2F1; natural killer cell receptor | |
Rabbit | |
Affinity chromatography | |
RUO | |
10219 | |
-20°C or -80°C if preferred | |
Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction